CKLF1-C27 (TFA)
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research[1].
Product Specifications
UNSPSC
12352209
Target
CCR; ERK
Type
Peptides
Related Pathways
GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cklf1-c27-tfa.html
Solubility
10 mM in DMSO
Smiles
OC(C(F)(F)F)=O.O=C([C@H]1N(CCC1)C(CNC([C@H](CO)NC([C@H]2N(CCC2)C([C@H](CC(N)=O)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@@H](N)C)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)=O)=O)=O
Molecular Formula
C153H244F3N39O39
Molecular Weight
3310.80
References & Citations
[1]Yaqi Tan, et al. Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One. 2015 Apr 27;10 (4) :e0125073.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
CCR4; ERK1; ERK2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
36426061 1.0 µg DNA
PFDN2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details